Trial reportBMC complementary medicine and therapies2026
Effect of Equine-assisted Biographical Work (EABW) in older adults with subclinical depression: a randomized controlled trial.
Trial report in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPreventive approaches for depression in adults aged 50 years and older have received little attention, despite increasing needs arising from demographic changes. In particular, subclinical depression is often underdiagnosed and associated with anxiety, a poorer quality of life, and greater need for assistance from the healthcare system.
objectiveThis multicentre, randomised, controlled phase III trial investigated if Equine-Assisted Biographical Work (EABW) is effective to improve subclinical depression.
methodsQualified sites in Germany enrolled 52 participants ≥ 50 years (Full Analysis Set (FAS), N = 50). The intervention received weekly sessions of EABW for 8 weeks. The control group was not treated. Follow-up was after 3 months. Participants in both groups had similar demographic and baseline characteristics. The primary endpoint was change in Beck Depression Inventory-II (BDI-II). Secondary target parameters included questionnaires, e.g., dealing with anxiety, behavioural avoidance, and state of health.
resultsThe pre-test BDI-II score averaged 20.92 (SD 5.99) in the intervention group and 22.36 (SD 6.80) in the control group with a highly significantly greater improvement after treatment (F = 15.21, p < 0.001, Cohen’s d = 1.80) for intervention group. This difference was maintained until the follow-up period (F = 15.23, p < 0.001, d = 1.43). This outcome was supported by an improvement of secondary endpoints at week 8: Beck Anxiety Inventory (F = 8.38, p < 0.001, d = 0.93), Ego-Integrity Questionnaire (F = 19.60, p < 0.001, d = 1.32), Questionnaire for Positive and Negative Spontaneous Thoughts (F = 9.95, p < 0.001, d = 1.07), Gratitude Questionnaire (F = 12.71, p < 0.001, d = 1.09), Cognitive Behavioural Avoidance Scale (F = 18.26, p < 0.001, d = 1.50), Reminiscence Functions Scale (identity, F = 7.93, p < 0.001, d = 0.93; problem-solving, F = 5.88, p = 0.004, d = 0.85), Short Form Health Survey (36) (mental, F = 8.41, p < 0.001, d = 1.11), General Self-Efficacy Scale (F = 9.44, p < 0.001, d = 0.89), Multidimensional Mood State Questionnaire. For the Short Form Health Survey (36) (physical, F = 0.17, p = 0.84, d = 0.11) and other subgroups of the Reminiscence Functions Scale (death preparation, bitterness revival, boredom reduction, intimacy, conversation, and teach) no differences were observed.
conclusionsEABW was able to achieve a significant and lasting treatment success. This approach may represent an innovative concept to prevent worsening of depressive symptoms, improve anxiety and quality of life. The gentle use of the horse as a medium turned out to be very effective in achieving therapeutic results and acted as a kind of gateway for therapeutic processes.
trial registrationGerman Clinical Trials Register DRKS00017010. Registered on 01 April 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.